Like everyone, people with type 2 diabetes and obesity suffer from depression and anxiety, but even more so. Researchers at Joslin Diabetes Center now have demonstrated a surprising potential contributor to these negative feelings – and that is the bacteria in the gut or gut microbiome, as it is known.
The incidence of anal cancer continues to rise. Despite making the headlines with Farrah Fawcett, people are still reluctant to discuss this important cancer. The majority of patients with this cancer are cured by a combination of treatment of radiation and chemotherapy.
Physicians from the University of Vermont Medical Center in Burlington undertook a prospective, randomized, double-blinded, placebo-controlled trial to see whether preemptive analgesia could help reduce pain and narcotic use following common anal rectal surgical procedures.
Las bacterias genéticamente manipuladas se muestran esperanzadoras como nuevo tratamiento contra el estreñimiento, descubrieron los investigadores del Centro para Medicina Personalizada de Mayo Clinic en un estudio realizado en ratones.
Genetically engineered bacteria are showing promise as a new treatment for constipation, researchers at the Mayo Clinic Center for Individualized Medicine have discovered in a mouse study. The finding is significant in part because there are few approved constipation remedies on the market. The research is published in Cell Host & Microbe.
Obesity, cardiovascular disease, and cancer often begin with early, subtle changes in cell metabolism. Now researchers at Tufts University have developed a non-invasive optical imaging technique that detects these changes, providing an early window of opportunity for new research and potential therapeutic development.
The Chronic Pancreatitis and Autologous Islet Cell Transplant Program, created by Chirag S. Desai, MD, is helping patients improve their quality of life by eliminating severe pain and reducing or ending the use of narcotic pain medications, while preventing brittle diabetes.
Nutrition 2018 will feature the latest research into how adding certain foods to our diet might help lower risk for diabetes, cancer, neurodegenerative diseases and other health issues.
The factors that contribute to overweight and obesity are complex, but one pattern is clear: having obesity during childhood increases the likelihood of having obesity as an adult. The Nutrition 2018 meeting will feature new research on factors that may contribute to childhood obesity, as well as factors that can help kids maintain a healthy weight.
Guidelines recommend breastfeeding as the best source of nutrition for most babies. The Nutrition 2018 meeting will feature new research findings on the nature of breast milk and how breastfeeding may affect the health of both moms and babies.
The University of Texas MD Anderson Cancer Center has named eight researchers to the third annual class of Andrew Sabin Family Fellows. As part of the Andrew Sabin Family Fellowship Program, each researcher will receive $100,000 in funding over two years. The Andrew Sabin Family Foundation established the program through a $30 million endowment to encourage creativity, innovation and highly impactful cancer research in four categories: basic science, clinical, physician-scientist, and population and quantitative science.
Un grupo de investigadores de Mayo Clinic y Exact Sciences Corporation terminaron un estudio de fase II para comparar un conjunto de marcadores del ADN frente a la alfafetoproteína, como método para analizar el cáncer de hígado.
Um grupo de pesquisadores da Mayo Clinic e da Exact Sciences Corporation concluiu um estudo de fase II que realizou uma comparação entre um conjunto de marcadores de DNA e a alfafetoproteína como método para testar o câncer de fígado. Os pesquisadores apresentaram suas conclusões na conferência Digestive Disease Week (Semana das doenças digestivas) de 2018, em Washington, D.C.
Cedars-Sinai investigators have for the first time identified a gas produced in gut that could improve the diagnosis and treatment of patients with two common intestinal illnesses—small intestine bacterial overgrowth (SIBO) and irritable bowel syndrome (IBS).
Targeted therapy with anti-VEGF and anti-EGFR antibodies both improve outcomes when added to chemotherapy in the treatment of colorectal cancer. However, some previous studies suggested the combination of the two antibodies may have a negative interaction. Those studies were done without selecting patients for KRAS mutations. Investigators from the ECOG-ACRIN Cancer Research Group led by Howard S. Hochster, MD, FACP, associate director for clinical research and director of gastrointestinal oncology at Rutgers Cancer Institute of New Jersey, explored the anti-VEGFR antibody ramucirumab in second-line treatment.
Penn Medicine researchers are calling for greater precision in Medicare performance reporting for patients with gastrointestinal bleeding following an evaluation of patients with the condition.
For 19 years, Lisa Thomas, former professional basketball player and Cedars-Sinai laboratory investigator of inflammatory bowel disorders and immunobiology, thought her glory days as a forward and center for collegiate and professional teams were behind her. And then she got a phone call that returned her to the hardwood courts of her youth. On June 9, Thomas will be one of 96 players from the now-defunct Women’s Professional Basketball League to be inducted as “Trailblazers” into The Women’s Basketball Hall of Fame.
An experimental drug that blocks abnormal neural communication after spinal cord injury could one day be the key to improving quality of life by improving bladder function, new research suggests.
Epitope Diagnostics is proud to introduce a new adrenocortocotropic hormone (ACTH) ELISA Kit, which measures ACTH levels with high sensitivity and robust assay performance characteristics.
A UCLA-led study has found how colon cancer alters its genes during development in order to avoid detection by the immune system, creating a specific genetic imprint in the process.
Research to be presented at the ASCO 2018 Annual Meeting suggests that a new treatment combination can extend survival for many patients with advanced colorectal cancer and that its efficacy compares favorably to single-agent approaches.
Microsatellite instability (MSI) and DNA mismatch repair (MMR) deficiencies can predict Lynch syndrome (LS) across tumor types, according to researchers from Memorial Sloan Kettering Cancer Center (MSK), who presented this retrospective data analysis in a press conference at the annual meeting of the American Society of Clinical Oncology. This finding suggests that LS is linked to more types of cancer than previously thought, prompting a call for germline testing for LS in all individuals with MSI-high (MSI-H)/mismatch repair deficient (MMR-D) tumors.
The University of Kansas Cancer Center will present preclinical evidence supporting Ciclopirox Prodrug (CPX-POM), an anti-cancer agent currently in Phase I clinical trials, at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
The rates of infection following colonoscopies and upper-GI endoscopies performed at U.S. outpatient specialty centers are far higher than previously believed, according to a Johns Hopkins study published online this month in the journal Gut.
Virtual colonoscopy (CT Colonography) — shown to increase colorectal cancer screening rates at a lower cost than standard colonoscopy — can help jump-start the transition to screening Americans starting at age 45 as new American Cancer Society Screening guidelines recommend.
The American Cancer Society this week changed its advice on getting screen for colorectal cancer and is recommending that screening start five years earlier, from age 50 to age 45.
Study published today the journal Cancer recommends colorectal cancer screening start at age 45, five years younger than currently recommended for both men and women of all races and ethnicities.
Obese children who consume at least two servings of any type of cow’s milk daily are more likely to have lower fasting insulin, indicating better blood sugar control, according to researchers at The University of Texas Health Science Center at Houston (UTHealth).
Health care providers, community members, and researchers from across New Jersey came together at the ‘Conference for Change’ event, hosted by the New Jersey Primary Care Association and sponsored by ScreenNJ to address the need to improve screening rates for colorectal and lung cancers.
Wolters Kluwer Health announced today a publishing partnership with the American College of Gastroenterology (ACG) that adds three titles to the Lippincott portfolio. Beginning in January 2019, Wolters Kluwer will publish ACG’s flagship scientific publication, The American Journal of Gastroenterology, as well as two additional official publications, Clinical and Translational Gastroenterology (CTG) and ACG Case Reports Journal.
A national retrospective study led by researchers at The University of Texas MD Anderson Cancer Center found no association between intensity of post-treatment surveillance and detection of recurrence or overall survival (OS) in patients with stage I, II or III colorectal cancer (CRC). Published in the Journal of the American Medical Association, the study is the largest of surveillance intensity in CRC ever conducted.
Chad Schrack, a Fight Colorectal Cancer advocate is walking from Washington, D.C. to Venice Beach, California to honor his wife, a colorectal cancer survivor and all those affected by the second-leading cancer killer in the U.S.
UC San Diego researchers have developed a test that can screen for pancreatic cancer in just a drop of blood. The test, which is at the proof-of-concept stage, provides results in under an hour. It's simple: apply a drop of blood on a small electronic chip, turn the current on, wait several minutes, add fluorescent labels and look at the results under a microscope. If a blood sample tests positive for pancreatic cancer, bright fluorescent circles will appear.
The U.S. Food and Drug Administration has approved the first non-opioid treatment to ease sudden withdrawal from opioids. Lucemyra was approved for up to 14 days of treatment for adults to ease common withdrawal symptoms like vomiting, diarrhea, muscle pain and agitation.
Polly’s Run, a fundraiser to support pancreatic cancer research, will take place Sunday, June 3, at Tiguex Park near Albuquerque’s Old Town. The event will feature a 5K run/walk that starts at 8:30 a.m. and a Kid’s K that starts at 9:30 a.m. All proceeds benefit the Polly Rogers Pancreatic Cancer Research Fund at The University of New Mexico Comprehensive Cancer Center.
A targeted therapy that has shown its power in fighting ovarian cancer in women including those with BRCA1 and BRCA2 mutations may also help patients with aggressive pancreatic cancer who harbor these mutations and have few or no other treatment options. An international team of researchers led by the Perelman School of Medicine and the Basser Center for BRCA at the University of Pennsylvania reported their findings this week in JCO Precision Oncology.
A new study by researchers from the University of Chicago Medicine shows that bacterial signals are crucial to the development of a precursor condition to leukemia, which can be induced by disrupting the intestinal barrier or by introducing a bacterial infection.
Researchers from Case Western Reserve University School of Medicine have discovered how unusually long strands of RNA help colon cancer cells avoid death, allowing unregulated growth. Unlike other RNAs, the intriguing strands do not appear to encode proteins and are termed “long non-coding RNAs” or “lincRNAs.”A new study showed some lincRNAs could be targeted by drug developers to halt colon cancer.
Mutations in genes that help repair damage to DNA may aid in predicting the prognosis of patients with bladder and other related cancers, according to researchers.
Do metastatic cancer tumors "break bad" or are they "born bad"? In a study publishing the week of May 14 scientists found that in the colorectal tumors they examined, invasive cancers are born to be bad, and this tendency can potentially be identified at early diagnosis.
Are abnormal intestinal microorganisms a risk factor for developing cognitive impairment? Researchers at Rush University Medical Center are trying to answer that question with a new study that will explore how the intestinal microbiota – the bacteria in the intestine –influence the progression of cognitive decline and the development of Alzheimer’s disease.
Queen’s University Belfast researchers at the Centre for Cancer Research and Cell Biology (CCRCB) alongside local company Fusion Antibodies plc have secured a prestigious Medical Research Council (MRC) award to develop a new antibody drug for the treatment of pancreatic cancer.
Scientists have for the first time found evidence that a microbe in the human gut is associated with protection from typhoid fever infection. If the research is borne out, it could offer an exciting new way to reduce these infections.